Halozyme Therapeutics Aktie
57,32
EUR
+0,02
EUR
+0,03
%
65,70
USD
-1,26
USD
-1,88
%
Werbung
Halozyme Therapeutics Aktie Analyse
15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC |
Werbung
Werbung